Captrust Financial Advisors Nuvation Bio Inc. Transaction History

Captrust Financial Advisors

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 16, 2022	SELL	$3.24 - $5.85 $145 - $263	-45 Reduced 14.61%	263 $1,000
Q1 2022 May 16, 2022	BUY	$4.6 - $8.83 $1,416 - $2,719	308 New	308 $2,000
Q3 2021 Nov 16, 2021	SELL	$7.78 - $10.0 $210 - $270	-27 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$9.22 - $14.48 $248 - $390	27 New	27 $0

152

123M

9.7K

6.5K

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $480M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.